Skip to main content
Premium Trial:

Request an Annual Quote

Biomax Buys Data-Mining Business from Eudaptics

NEW YORK (GenomeWeb News) - Biomax Informatics said today that it has purchased the Viscovery software business of Austrian firm Eudaptics Software for an undisclosed sum.
 
"Eudaptics had previously transferred its operative business to Viscovery Software," Biomax explained, adding that Viscovery "will continue to operate as a self-contained company within the Biomax group, so that there will be no changes in the business relations for new and existing customers."
 
Biomax, based in Martinsried, Germany, sells knowledge management software, and said the Viscovery product line provides "a visual approach to data exploration.”
 
The company said that the combination of its BioXM platform with Viscovery will be particularly useful "for areas such as biomarker identification, toxicology and clinical research."
 
The transaction is expected to expand both companies' products into new markets.
 
"The merger with Biomax allows Viscovery to access the rapidly growing life science market,” said Viscovery's managing director, Gerhard Kranner, in a statement. “In addition, the BioXM platform may be deployed as an effective solution in markets where Viscovery is already firmly established.”
 
Viscovery will continue to develop its data-mining software, and said updates and new offerings will be made available to existing and new customers.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.